J&J’s COVID-19 shot may be connected to rare autoimmune disorder: report

0

Shares of Johnson & Johnson
JNJ,
-0.16%
were down 0.2% on Monday after the Washington Post reported that U.S. regulators plan to issue a new safety warning for the company’s COVID-19 shot. The adenovirus viral vector, single-shot vaccine may be tied to rare instances of Guillain-Barré syndrome. The Post, citing data from the Centers for Disease Control and Prevention, reported that there have been 100 cases of the autoimmune disorder among the roughly 12.6 million people who have received the J&J shot. The vaccine, which received emergency authorization in February, has struggled to gain its footing among Americans after manufacturing issues at a plant in Maryland and a confirmed association with ultra-rare blood clots. J&J’s stock is up 7.7% so far this year, while the broader S&P 500
SPX,
+0.35%
has gained 16.3%.

Source

- Advertisement -

Leave A Reply

Your email address will not be published.